The use of low-dose topiramate in combination with low-dose phentermine for weight loss is an off-label use of topiramate in New Zealand (
The controlled-release formulation of phentermine and topiramate at low, medium and full doses (with full dose containing 15 mg of phentermine hydrochloride and
Fourteen and 10 patients were assigned to the low-dose phentermine and placebo groups, respectively. Patients taking low-dose phentermine and placebo patients were an average of days, respectively, into treatment. Patients taking low-dose phentermine were on average 43.42 3.9 years of age.
Fourteen and 10 patients were assigned to the low-dose phentermine and placebo groups, respectively. Patients taking low-dose phentermine and placebo patients were an average of days, respectively, into treatment. Patients taking low-dose phentermine were on average 43.42 3.9 years of age.
The controlled-release formulation of phentermine and topiramate at low, medium and full doses (with full dose containing 15 mg of phentermine hydrochloride and
The controlled-release formulation of phentermine and topiramate at low, medium and full doses (with full dose containing 15 mg of phentermine hydrochloride
The controlled-release formulation of phentermine and topiramate at low, medium and full doses (with full dose containing 15 mg of phentermine hydrochloride
The controlled-release formulation of phentermine and topiramate at low, medium and full doses (with full dose containing 15 mg of phentermine hydrochloride and
The use of low-dose topiramate in combination with low-dose phentermine for weight loss is an off-label use of topiramate in New Zealand (
Comments